AMAG up +2.94% percent Today $AMAG High is at 35.07 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 11:45 AM

AMAG up +2.94% percent Today $AMAG High is at 35.07 and the Low 33.95 with current volume of 119,137.

Recent News posted below.

Amag Pharmaceuticals AMAG other info.
http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/

AMAG Amag Pharmaceuticals Recent Headline News

Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 2 mins ago
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 304.87 (-0.56), KITE: 39.15 (-0.19), ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76)

Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 59 mins ago
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43), PBYI: 216.91 (+0.69)

Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 304.87 (-0.56), ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)

AMAG Pharmaceuticals Announces Presentation at Jefferies 2014 Global Healthcare Conference in London
GlobeNewswire - Fri Nov 14, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Thursday, November 20, 2014 at 9:20 a.m. GMT. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed, including the acquisition of the maternal health business of Lumara Health Inc.
AMAG: 34.76 (+0.76)

AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 40.24 (+0.19), AVEO: 0.95 (+0.01), AMAG: 34.76 (+0.76)

AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.28 (+0.12), AZN: 71.99 (-0.86), AMGN: 158.61 (+0.93), AMAG: 34.76 (+0.76)

Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 55.34 (+1.39), ICPT: 157.05 (-5.53), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)

Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 304.87 (-0.56), ALNY: 88.96 (-1.16), ILMN: 180.07 (-0.43), AMAG: 34.76 (+0.76)

AMAG Pharmaceuticals Completes Acquisition of Lumara Health's Maternal Health Business
GlobeNewswire - Wed Nov 12, 3:03PM CST
-- AMAG Closes $340 Million Term Loan
AMAG: 34.76 (+0.76)

Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.28 (+0.12), GILD: 100.60 (-1.46), ACHN: 13.46 (-0.51), AMAG: 34.76 (+0.76)

AMAG Pharmaceuticals Has Returned 67.4% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Tue Nov 11, 10:58AM CST
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 67.38% as of today's recent price of $34.99.
AMAG: 34.76 (+0.76)

Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:20AM CST
Orexigen (OREX) swung to profit in the third quarter of 2014 with earnings of 9 cents per share beating the Zacks Consensus Estimate of 5 cents.
OREX: 5.52 (-0.13), VVUS: 3.11 (-0.14), AMAG: 34.76 (+0.76)

Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 304.87 (-0.56), OREX: 5.52 (-0.13), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)

PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:20AM CST
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.76 (+0.76), SNY: 47.29 (+0.61), PDLI: 7.88 (+0.09)

Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 4.20 (-0.03), BIIB: 304.87 (-0.56), OSIR: 13.23 (+0.18), AMAG: 34.76 (+0.76)

Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 304.87 (-0.56), RPRX: 9.23 (-0.11), ABBV: 65.01 (+1.01), AMAG: 34.76 (+0.76)

Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.76 (+0.76), TBPH: 17.87 (+0.39), GSK: 45.82 (+0.08), THRX: 13.18 (-0.05)

BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 2.95 (-0.03), AMAG: 34.76 (+0.76), BIND: 10.20 (-0.06), AFFX: 9.28 (-0.43)

Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 2.95 (-0.03), BIIB: 304.87 (-0.56), AMAG: 34.76 (+0.76), KERX: 15.18 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Abbott's Oncodetect Test: Game-Changer for Cancer Recurrence

Pioneering Progress in Colorectal Cancer Detection There's a new player in the world of cancer diagnostics, and it's setting a fresh standard. Abbott's Oncodetect test, featured at the ESMO Congress, has shown a profound leap in sensitivity—30 percent over the older whole-exome sequencing approach. For those doing the math on the stock charts, Abbott (NYSE: ABT) is...

Gala Spotlights Veterans' Mental Health Support

Champions for Veterans Honored at Headstrong Gala If you ever wondered who stands in the trenches alongside veterans facing mental health battles, this year's Headstrong Gala offered a crystal-clear answer. Held on October 16 at Pier Sixty in New York City, this shiindig wasn’t just about schmoozing over canapés. It was about celebrating the grit and guts of those...

Navigating Home Sales: Expert Insights from Jodi Kallus

Preparing for the Real Estate Rollercoaster Getting ready to sell your home? Let's cut through the noise and get right into the nitty-gritty with Jodi Kallus, a seasoned real estate pro with Summit Realtors. The first step ain't just about slapping a ‘For Sale’ sign on your front lawn. It's about laying down a plan that's as solid as the foundation of the house you're...

Infosys Pushes AI Growth with Strong Deal Wins

Riding the AI Wave Who knew Infosys was a lightning rod for AI momentum, eh? With a 29% quarterly surge in AI revenue, the firm's really putting AI strategy at center stage. Considering today's finicky markets, that's not just peanuts. CEO Salil Parekh's swagger is backed by real numbers, seeing AI revenue inch to 10.5% of total haul. This ain't just talk—Infosys is...

Ping An Good Doctor Grows 35%: AI's Expanding Role

Ping An Good Doctor's Noteworthy Financial Uptick Stop me if you've heard this one: a hefty hike in numbers that make investors straighten up a bit. Ping An Good Doctor did just that, reporting a 35% spark in net profit as the books closed up till September 2026. In a landscape where many health-tech firms merely tread water, these guys rode a wave of RMB 0.25 billion in...

Palmstreet Amplifies Designer Toys at Las Vegas Con

Designer Toys Take the Spotlight Palmstreet's latest move into the designer toy world is buzzing with anticipation. This live-shopping app, initially catering to rare plants, is taking its evolution seriously with another plunge into exclusive collectibles, this time showcasing unique collaborations at DesignerCon in Las Vegas. While Palmstreet may have started in a...

Lincoln Educational Faces Investor Lawsuit Over Revenue Drop

Investors Face Rough Waters Okay, let’s dive into this latest mess at Lincoln Educational Services Corp. (NASDAQ:LINC). Things aren't smelling too rosy over at their headquarters. If you've got shares here, you’ll know what I mean. Back in early May, the folks running Lincoln threw a garden party talking up a 19.5% growth in student starts. Who wouldn’t get behind...

Unicoin’s 'RISE IN PINK' Blends Crypto and Charity

The New Face of Charitable Giving: Crypto and Cause Turning the spotlight on how blockchain and altruism can mesh, Unicoin's latest campaign isn’t just your average philanthropic endeavor. With 'RISE IN PINK', they're out to change the game, blending digital assets with a deep human cause—breast cancer awareness and support. Technology Meets Human Cause Imagine...

S&P Global's New Dashboard: Unpacking Data Insights

An Interactive Take on Digital Infrastructure The geniuses over at S&P Global Ratings have just unleashed a shiny new tool for number crunchers and market hawks who can't get enough data center action—an interactive dashboard. Maybe not everyone’s cup of tea, but hey, in the dog-eat-dog world of digital infrastructure, any edge counts. What's in the Data Center Soup?...

Patrick Ta Beauty Adds New Leadership to Expand Growth

Angela Simpson and Carolyne Rapp Join the Ranks In the fast-paced world of beauty, where trends shift faster than a day trader’s mood, Patrick Ta Beauty is shaking things up with some heavyweight hires. Angela Simpson steps in as Chief Marketing Officer, and Carolyne Rapp takes the reins as Vice President of Creative. Maybe it’s just me, but when a brand ropes in pros...